Abstract
Introduction
In both rodent and non-human primate models of Parkinson's disease (PD), viral vector-mediated gene delivery of one or three dopamine (DA)-synthesizing enzyme(s) into the striatum has been shown to ameliorate motor symptoms with efficient transduction of putaminal neurons (Shen et al., 2000; Muramatsu et al., 2002; Sun et al., 2004 : Li et al., 2006 Bankiewicz et al., 2006; Svendsen, 2007; Fiandaca et al., 2008) .
In addition to tyrosine hydroxylase (TH) and aromatic L-amino-acid decarboxylase (AADC), GTP cyclohydrolase I (GCH) is necessary for efficient DA production (Shen et al., 2000; Muramatsu et al., 2002; Sun et al., 2004; Iancu et al., 2005) . Using adeno-associated virus (AAV) vectors, two phase 1 clinical investigations of gene therapy for PD are underway based on these animal studies (Christine et al., 2009; Muramatsu et al., 2010b) . In these protocols, gene transfer of AADC into the human putamen is combined with oral administration of L-3,4-dihydroxyphenylalanine (L-dopa). Expression of AADC would convert L-dopa to DA in the putamen. However, the mechanism of DA release from transduced cells remains to be elucidated.
Nerve terminals from dopaminergic neurons of the substantia nigra (SN) are selectively degraded and mostly lost in the putamen of PD (Nagatsu and Ichinose, 1999) . This indicates that DA synthesized by extrinsic enzymes could be released from the soma of transduced neurons or astrocytes, in which the fusion of exocytotic vesicles and vesicular secretory apparatus are not completely identical to those in the nerve terminals (Montana et al., 2006) . Therefore, we postulated another mechanism in which a complex of proteolipid channels in SNARE fusion as described in yeast and Drosophila (Peters et al., 2001; Almers, 2001; Hiesinger et al., 2005) is effective in DA secretion from gene therapeutically DA-expressing cells in the striatum.
To assess the validity of this mechanism, we used mediatophore, a 16-kDa proteolipid originally found in the presynaptic membrane of the Torpedo electric organ (Israel et al., 1986 and 1991) . Mediatophore was later shown to be an ortholog of mammalian C subunit in the V0 transmembrane sector of vacuolar proton ATPase (ATP6V0C; Nezu et al., 1992; Dunant & Israel, 2000; Hinton et al., 2009; Ediger et al., 2009; Di Giovanni et al., 2010; El Far and Seagar, 2011) . ATP6V0C forms a proteinaceous pore (Zimmerberg, 2001; Dunant & Israel, 2000; have been reported (Di Giovanni et al., 2010; El Far and Seagar, 2011) .
However, the roles of ATP6V0C in the central nervous system on DA secretion have not yet been reported.
Here, we examined the effects of ATP6V0C on DA release in the mouse striatum after transfection with AAV harboring ATP6V0C and DA-synthesizing enzymes (Muramatsu et al., 2002) . We examined the effects of ATP6V0C on motor behavior in a unilateral 6-hydroxydopamine (6-OHDA)-lesioned mouse model of PD. Furthermore, we examined DA release more directly using cultured neuronal cells. NG108-15 neuroblastoma × glioma hybrid (Nirenberg et al., 1983a and b; Higashida et al., 1986) and C6 glioma cells possess ATP6V0C, while no such protein was detected in N18 neuroblastoma clonal cells (Amano et al., 1972; Falk-Vairant et al., 1996a and b) . It has been reported that ACh is not synthesized in N18 cells (Amano et al., 1972) and that ACh is not released from transformed N18 cells to express choline acetyltransferase (Zhong et al., 1995a and b) but released from N18 cells forced to express ATP6V0C (Falk-Vairant et al., 1996a and b) . Therefore, we examined whether 
Experimental procedure

Animals
Wild-type adult male mice of the ICR strain were kept in the animal center under standard conditions (24°C; 12-h light/dark cycle, lights on at 08:00) and received food and water ad libitum. The experiments were carried out in accordance with the Guidelines for the Care and Use of Laboratory Animals of Kanazawa University.
6-Hydroxydopamine-lesioned mice
Mice were anesthetized with sodium pentobarbital (50 mg/kg, i.p.) and placed in a stereotaxic apparatus. A small hole was made in the skull using a dental drill, and a 25-gauge stainless steel injection needle was inserted into the right striatum. A 2-µL aliquot of 6-OHDA dissolved in 0.02% ascorbic acid in saline was injected into the substantia nigra over a period of 2 min at a speed of 1 µL/min (total injected amount: 28 µg of 6-OHDA). The needle was left in place for an additional 3 min and then withdrawn slowly. Control animals received PBS into the substantia nigra according to the same procedure.
To validate that 6-OHDA effectively induced DA depletion, 
Production and use of AVV
For generation of AAV vectors, we used vector plasmids containing an expression cassette, in which a human cytomegalovirus immediate-early promoter (CMV promoter) was followed by the first intron of the human growth hormone gene, the cDNA of TH, AADC, GCH, forward or reverse form ATP6V0C (Nezu et al., 1992) 
Infection with AAV
AAV vector expressing either forward or reverse form of ATP6V0C was injected stereotaxically into the bilateral caudoputamen (CPU) of intact mice. Phosphate buffer solution (PBS) was injected in the CPU of control mice. In other experiments, mixtures of three separate AAV vectors expressing TH, AADC, and GCH, or in addition of two types of ATP6V0C, were injected stereotaxically into the unilateral CPU of hemiparkisonian mice six weeks after the 6-OHDA treatment.
In vivo microdialysis
Wild-type ICR mice (11 -13 weeks old; n = 6 -8) were
anesthetized with sodium pentobarbital (50 mg/kg, i.p.), and a guide cannula (AG-4; Eicom Corp., Kyoto, Japan) was implanted into the CPU potassium-containing aCSF (50 mM; isomolar replacement of NaCl with KCl) was perfused for 20 min through the dialysis probe. DA levels in the dialysates were analyzed using an HPLC system (HTEC-500; Eicom
Corp.) equipped with an electrochemical detector, as described previously (Jin et al., 2007) . The probe recoveries of DA were approximately 25%.
Immunostaining of brain sections
Brains were perfused with 4% paraformaldehyde, soaked in 30% sucrose, and dissected into coronal sections (30 µm). TH monoclonal antibody (1:800 or 1:8000; DiaSorin, Stillwater, MN) was used.
Appropriate fluorescence-tagged (Invitrogen, Carlsbad, CA) or biotinylated (Vector Laboratories, Burlingame, CA) secondary antibodies were used for visualization. Immunoreactivity was assessed under microscopy (Olympus, Tokyo, Japan).
Motor behavior test with the rotating rod
The degrees of motor impairment were evaluated by measuring latency until falling from an accelerating rotating rod (diameter, 3 cm), the speed of which was slowly increased from 3 to 30 rpm within 5 min (Rotarod Apparatus Model MK-670; Muromachi Kikai, Tokyo, Japan). For 3 days before the 6-OH-injection to produce the nigra-caudate lesion, all mice were habituated to the rotarod test to minimize novelty stress and to achieve similar performance in the task. The time until falling off the rotating rod was measured.
Amphetamine-induced rotation test
d-amphetamine-induced rotation was used to estimate the extent of DA release in the striatum on three successive days three weeks after vector injection. d-amphetamine (3 mg/kg) was administrated intraperitoneally to the mice that had been treated with AAV vectors expressing TH, AADC, GCH, forward or reverse form ATP6V0C in the lesion side of the striatum. The criterion for ipsilateral abnormal rotation was more than 10 full turns per minute over 30 minutes on each examination day, as described previously (Imamura et al., 2003) .
Experiments on release of [ 3 H]DA
N18 neuroblastoma and NG108-15 hybrid cells (Amano et al., 1972; Nirenberg et al., 1983a; Suzuki et al., 1983) were grown for 6 days in the presence of 1 mM dibutyryl cyclic AMP on 60-mm polyornithine-coated dishes (Higashida et al., 1986) . The experiment was performed in the presence of 10 µM pargyline, as described previously (Furuya et al., 1985) . Cultures were incubated with PBS for 30 min at 37°C.
After rinsing, they were incubated with 1 µM for NaCl. CaCl 2 (1.8 mM) was omitted and 0.1 mM EGTA was added in some incubations. After the end of each 4-min period, the incubation medium was removed and fresh medium was added to the cultures. The incubation medium was passed through a 3 × 1 cm Sephadex G-10 column and eluted with 6 mL of H 2 O followed by 3.1 mL of 0.5 M formic acid. The radioactivity in each fraction was estimated by liquid scintillation spectrometry.
Statistical analysis
All results are expressed as means ± SEM. One-tailed t test and one-way ANOVA combined with the Bonferroni test were used to analyze data with unequal variance between groups using the Stata data analysis and statistical software (StataCorp, College Station, TX). In all analyses, P < 0.05 was taken to indicate statistical significance.
Effects of ATP6V0C on DA release in intact mice
To identify functional roles of ATP6V0C in the central nervous system, we expressed ATP6V0C in the mouse brain using the constructed AAV vectorsharboring cDNAs of rat ATP6V0C, its reverse form, and ATP6V0C-GFP. Infection of these viruses in the substantia nigra of the intact mouse brain revealed ATP6V0C-GFP expression in both TH-positive neurons and TH-negative cells, probably astrocytes (Fig. 1a -c ).
Based on this information, DA overflow from the synaptic cleft in the striatum of mice treated with AAV vectors in the substantia nigra was measured by the in vivo microdialysis method. DA release was significantly higher in the mice infected with AAV-ATP6V0C under both resting (at 5 mM of extracellular potassium concentration) and depolarizing (50 mM) conditions ( Fig. 2 ; n = 6 -8, one-way ANOVA, F 5,49 = 19.96 *P < 0.05 or **P < 0.001). Viral infection with reverse direction of ATP6V0C had no or little effect on DA release, comparable to the control (sham-operated with PBS injection) mice. We used reverse ATP6V0C as an additional control, instead of controls with vector alone, in the subsequent experiments.
Behaviors in hemiparkinsonian mice with or without ATP6V0C
Next, we examined the effects of ATP6V0C on recovery from motor impairment elicited in a unilateral 6-OHDA-lesioned mouse model of PD, in which AAV vectors of two types of ATP6V0C in addition to DA synthetic enzymes, TH, AADC, and GCH were infected on the striatum.
Motor performance of 6-OHDA-treated mice was examined based on the latency to fall from the rotarod. 6-OHDA mice treated with 3 DA-synthesizing enzymes and ATP6V0C showed significantly improved performance on the rotarod compared with control lesioned mice treated with PBS alone (Fig. 3) . The mean recovery by enzymes, enzymes with reversed ATP6V0C, and enzymes with ATP6V0C was to 43, 45 and 77% levels from 19% of the ability of the intact mice, respectively (* , ** , ***P < 0.05, 0.01 and 0.001, respectively; F 4,20 = 40.42, P < 0.001; n = 5).
As d-amphetamine-induced rotation shows the highest predictability of nigral TH cell loss (Iancu et al., 2005; Fleckenstein et al., 2007) , we next examined the effects of amphetamine. Three weeks after lesion generation, mice exhibited ipsilateral turning induced by intraperitoneal injection of 3 µg/kg of d-amphetamine (Fig. 4) . The number of rotations was significantly decreased in mice transfected with 3 enzymes (14.9 ± 1.2 rotations/3 min), 3 enzymes plus reverse ATP6V0C (13.9 ± 4.3), and 3 enzymes plus ATP6V0C (4.0 ± 1.0), compared with control mice injected with PBS (31.7 ± 2.0) (one-way ANOVA, F 3,12 = 55.44, P < 0.001. *P < 0.01, **P < 0.002, and ***P < 0.001, respectively (n = 4)). In sham-operated mice, no rotation was induced by amphetamine (n = 4).
[ 3 H]DA release from N18 cells expressing ATP6V0C or NG108-15 cells
Finally, we tested the hypothesis of [ 3 H]DA release through ATP6V0C in vitro. We cultured N18 neuroblastoma cells, which have no endogenous ATP6V0C (Falk-Vairant et al., 1996a and b) and no ACh release capacity (Zhong et al., 1995a and b; Falk-Variant et al., 1996a and b) . The cells were preloaded for 1 h in 1 µM [ 3 H]DA in the presence of pargyline (Furuya et al., 1985) . The release of [ 3 H]DA and its metabolites were measured. As expected, an increase in K + concentration in the perfusion medium to 80 mM (at 20 and 24 min) resulted in no detectable increase in release, compared from concentrations in the other period (one-way ANOVA, F 7,16 = 2.89, P = 0.037; Fig. 5a ). However, when identical experiments were performed in N18 cells transfected with ATP6V0C, [ 3 H]DA was released due to high-potassium stimulation in a Ca 2+ -dependent manner (F 8,27 = 18.61, P < 0.001 (Fig. 5b) ). 
NG108-15 neuroblastoma
Discussion
The results of the present study demonstrated for the first time that DA could be released from nigrostriatal cells overexpressing ATP6V0C of mice and from cultured neuronal cells endogenously or exogenously expressing ATP6V0C in a Ca 2+ -dependent manner. The precise mechanism underlying the Ca 2+ -dependent DA release is not yet clear. However, as ATP6V0C binds to syntaxin in SNARE complexes (Shiff et al., 1996) or shows direct interaction with v-SNARE synaptobrevin (Di Giovanni et al., 2010; El Far and Seagar, 2011) , ATP6V0C may cooperate with SNARE proteins and vesicles for release at the late stage of fusion. Our finding of DA release through proteolipid fusion pores suggested that the vesicles may be recycled without undergoing full fusion with the plasma membrane,
i.e., the "kiss-and-run" process (Ales et al., 1999; Fesce and Meldolesi, 1999; Valtorta et al., 2001; Rizo and Rosenmund, 2008) .
PD is a common neurodegenerative disorder in the elderly (Samili et al., 2004) . Characteristic motor symptoms, which include resting tremor, muscular rigidity, and bradykinesia, are caused by a severe decrease in the DA content of the striatum secondary to progressive loss of nigrostriatal DA neurons (Santini et al., 2009) . Replacement of DA in the striatum is important for functional recovery regardless of damage sustained by the nigrostriatal DA pathway. With recombinant AAV vectors, gene therapy is becoming a feasible therapeutic option for PD (Lees et al., 2009; Muramatsu et al., 2010a) .
Efficient and long-term expression of genes for DA-synthesizing enzymes in the striatum restored local DA production and allowed behavioral recovery in animal models of PD (Muramatsu et al., 2002) .
Baseline striatal dopaminergic neurotransmission in the normal striatum is maintained by tonic synaptic and non-synaptic DA release, which is largely independent of changes in neuronal impulse flow in the nigrostriatal pathway. As in previous studies (Shen et al., 2000; Muramatsu et al., 2002; Bankiewicz et al., 2006) , the majority of transduced cells were neurons. As most of the striatal neurons express DA receptors that are internalized in response to alterations in dopaminergic tone (Dumartin et al., 1998; Muriel et al., 1999) , DA produced in striatal neurons may bind to cytoplasmic DA receptors. However, we previously detected efficient baseline and L-dopa-induced DA release in the AAV-TH/-AADC/-GCH-injected putamen by microdialysis (Muramatsu et al., 2002) , suggesting that the DA synthesized by these extrinsic enzymes was released by a non-synaptic mechanism or from non-neuronal elements such as astroglial cells. To our knowledge, these results represent the first insight into the possible involvement of ATP6V0C in these phenomena.
We demonstrated that ATP6V0C expression in the striatum increased endogenous DA release due to depolarization in the intact brain (Fig. 2) . However, we did not measure DA release in the 6-OHDA-lesioned brain with the same paradigm. Therefore, it will be interesting if we can show an evidence of recovery at the DA release level using in vivo microdialysis for ameliorating behavioral impairments with 3 enzymes and/or ATP6V0C. Such experiments currently underwent.
The results of the present study indicated that DA is similarly released from N18 neuroblastoma cells expressing ATP6V0C and NG108-15 cells with endogenous ATP6V0C and dense core vesicles (Furuya et al., 1985) (Suzuki et al., 1983; Furuya et al., 1985) . Therefore, it is possible that serotonin and DA share the ATP6V0C-dependent mechanism for release from NG108-15 cells.
In conclusion, we observed better improvement in movement impairment in mice expressing 4 proteins (TH, AADC, GCH, and ATP6V0C) than 3 (TH, AADC, and GCH). This concept of additional effects with ATP6V0C suggested that ATP6V0C may be useful in future gene therapy for PD, in addition to TH, AADC, GCH, and the DA transporter (Sun et al., 2004) .
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